Brought to you by 
Affimed signs innate cell antibody engager deal with Genentech
01 Jul 2020
Executive Summary
Affimed NV and Roche’s Genentech Inc. agreed to discover and conduct early- and late-stage research on innate immune cell--natural killer (NK) cell and T-cell--immunotherapies against certain Genentech-selected targets for various solid and hematological tumors. Genentech will take over clinical development and hold exclusive global commercialization rights; it is also responsible for related costs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com